Of these five drugs only orlistat is current available in the UK, whilst liraglutide has been approved by the European Medicines Agency but has not yet launched in UK.
Authors of an editorial note that limitations of the analysis include the shortage of direct comparative studies and the high attrition rates in all trials (30-45%), which reduces the robustness of the evidence.